Fig 3.

After cell infusion, T-cell receptor (TCR)–transduced T cells persisted better in the high-dose group compared with the low-dose group. (A) Peripheral blood lymphocyte (PBL) samples before (top) and approximately 1 month after (bottom) T-cell therapy were stained with anti-mouse TCRβ constant region antibody (mTCRβ) to detect MAGE-A3 (melanoma-associated antigen-A3) TCR-transduced T cells. A representative result is shown. (B) Percentage of CD4⁺mTCRβ⁺ cells in lymphocyte populations at approximately 1 month in the low-dose and high-dose patients. (C) Cell numbers of CD4⁺mTCRβ⁺ cells in patients’ peripheral blood. The post-treatment PBL sample from patient 4 was not available. Statistical significance was determined by Mann-Whitney U test. Patients who experienced objective responses are labeled with gray circles. CR, complete response; PR, partial response.